PCVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vaxcyte Inc (PCVX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has promising analyst ratings and potential catalysts, the technical indicators are neutral, and the financial performance shows significant losses. The options data also indicates bearish sentiment. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on investing in this stock is recommended until clearer bullish signals emerge.
The stock's MACD is negatively expanding, RSI is neutral at 48.775, and the price is below the pivot level of 61.32, suggesting a lack of strong upward momentum. However, the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 59.75, and resistance is at 62.89.
Analysts have raised price targets significantly, citing the strong potential of VAX-31 and upcoming Phase 3 adult data as key de-risking catalysts. The company's differentiated Phase II data and comprehensive Phase III program are viewed positively.
No recent news or significant insider or hedge fund activity. The financial performance shows substantial losses, with no revenue growth and negative EPS. Options data indicates bearish sentiment, and the stock trend suggests potential short-term declines.
In Q4 2025, revenue remained at 0 with no growth. Net income improved YoY but is still significantly negative at -$246.5 million. EPS also improved YoY but remains negative at -1.81. Gross margin is 0, indicating no profitability.
Analysts are generally bullish, with multiple firms raising price targets (e.g., TD Cowen to $75, Goldman Sachs to $67, BofA to $133, and BTIG to $89). They cite the strong potential of VAX-31 and upcoming clinical data as key drivers. However, Goldman Sachs maintains a Neutral rating, highlighting some caution.
